000850919 001__ 850919
000850919 005__ 20220930130154.0
000850919 0247_ $$2doi$$a10.1007/s12035-018-1209-3
000850919 0247_ $$2ISSN$$a0893-7648
000850919 0247_ $$2ISSN$$a1559-1182
000850919 0247_ $$2Handle$$a2128/21947
000850919 0247_ $$2pmid$$apmid:30003517
000850919 0247_ $$2WOS$$aWOS:000460163700049
000850919 0247_ $$2altmetric$$aaltmetric:45295266
000850919 037__ $$aFZJ-2018-04653
000850919 082__ $$a570
000850919 1001_ $$0P:(DE-Juel1)165908$$aSchemmert, Sarah$$b0$$ufzj
000850919 245__ $$aAβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology
000850919 260__ $$aTotowa, NJ$$bHumana Press$$c2019
000850919 3367_ $$2DRIVER$$aarticle
000850919 3367_ $$2DataCite$$aOutput Types/Journal article
000850919 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1553882314_25990
000850919 3367_ $$2BibTeX$$aARTICLE
000850919 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000850919 3367_ $$00$$2EndNote$$aJournal Article
000850919 520__ $$aOligomers of the amyloid-β (Aβ) protein are suspected to be responsible for the development and progression of Alzheimer’s disease. Thus, the development of compounds that are able to eliminate already formed toxic Aβ oligomers is very desirable. Here, we describe the in vivo efficacy of the compound RD2, which was developed to directly and specifically eliminate toxic Aβ oligomers. In a truly therapeutic, rather than a preventive study, oral treatment with RD2 was able to reverse cognitive deficits and significantly reduce Aβ pathology in old-aged transgenic Alzheimer’s Disease mice with full-blown pathology and behavioral deficits. For the first time, we demonstrate the in vivo target engagement of RD2 by showing a significant reduction of Aβ oligomers in the brains of RD2-treated mice compared to placebo-treated mice. The correlation of Aβ elimination in vivo and the reversal of cognitive deficits in old-aged transgenic mice support the hypothesis that Aβ oligomers are relevant not only for disease development and progression, but also offer a promising target for the causal treatment of Alzheimer’s disease.
000850919 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000850919 588__ $$aDataset connected to CrossRef
000850919 7001_ $$0P:(DE-Juel1)166069$$aSchartmann, Elena$$b1
000850919 7001_ $$0P:(DE-Juel1)162137$$aZafiu, Christian$$b2$$ufzj
000850919 7001_ $$0P:(DE-Juel1)171532$$aKass, Bettina$$b3$$ufzj
000850919 7001_ $$0P:(DE-HGF)0$$aHartwig, Sonja$$b4
000850919 7001_ $$0P:(DE-HGF)0$$aLehr, Stefan$$b5
000850919 7001_ $$0P:(DE-Juel1)157832$$aBannach, Oliver$$b6$$ufzj
000850919 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b7$$ufzj
000850919 7001_ $$0P:(DE-Juel1)131794$$aShah, Nadim Joni$$b8$$ufzj
000850919 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b9$$ufzj
000850919 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b10$$eCorresponding author$$ufzj
000850919 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b11$$eCorresponding author
000850919 773__ $$0PERI:(DE-600)2079384-4$$a10.1007/s12035-018-1209-3$$n3$$p2211-2223$$tMolecular neurobiology$$v56$$x0893-7648$$y2019
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.pdf
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.gif?subformat=icon$$xicon
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.jpg?subformat=icon-1440$$xicon-1440
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.jpg?subformat=icon-180$$xicon-180
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.jpg?subformat=icon-640$$xicon-640
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.pdf?subformat=pdfa$$xpdfa
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/Schemmert2018_Article_A%CE%B2OligomerEliminationRestoresC.pdf$$yOpenAccess
000850919 8564_ $$uhttps://juser.fz-juelich.de/record/850919/files/Schemmert2018_Article_A%CE%B2OligomerEliminationRestoresC.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000850919 8767_ $$82936122539$$92018-07-30$$d2018-08-07$$eHybrid-OA$$jZahlung erfolgt
000850919 909CO $$ooai:juser.fz-juelich.de:850919$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165908$$aForschungszentrum Jülich$$b0$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162137$$aForschungszentrum Jülich$$b2$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171532$$aForschungszentrum Jülich$$b3$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)157832$$aForschungszentrum Jülich$$b6$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b7$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b8$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b9$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b10$$kFZJ
000850919 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b11$$kFZJ
000850919 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000850919 9141_ $$y2019
000850919 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000850919 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000850919 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000850919 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL NEUROBIOL : 2017
000850919 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000850919 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000850919 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000850919 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000850919 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL NEUROBIOL : 2017
000850919 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000850919 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000850919 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000850919 920__ $$lyes
000850919 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x0
000850919 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000850919 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x2
000850919 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x3
000850919 9801_ $$aAPC
000850919 9801_ $$aFullTexts
000850919 980__ $$ajournal
000850919 980__ $$aVDB
000850919 980__ $$aUNRESTRICTED
000850919 980__ $$aI:(DE-Juel1)ICS-6-20110106
000850919 980__ $$aI:(DE-Juel1)INM-4-20090406
000850919 980__ $$aI:(DE-Juel1)INM-11-20170113
000850919 980__ $$aI:(DE-82)080010_20140620
000850919 980__ $$aAPC
000850919 981__ $$aI:(DE-Juel1)IBI-7-20200312